Potential Failure of Novel-generation Oral Anticoagulants in Preventing Pulmonary Embolism: A Case Report and Current Literature Review

In this case report, we evaluated the risk of pulmonary embolism in patients using new -generation anticoagulant drugs. Laboratory tests for follow-up and effective dose measurement of new -generation oral anticoagulants, which are very popular in the medical community today, are not available. Therefore, patients can be at risk for effective doses and drug selection. Although our cases received novel oral anticoagulant treatment, it was determined that they had thromboembolism. We emphasized that we do not have enough information about the complications and effective use of these drugs, which are advantageous in terms of use and side effects. This situation may lead us to negative situations that we cannot manage in the future.